Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2005, p. 2716-2719, Vol. 49, No. 7
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.7.2716-2719.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Service de Microbiologie and EA 2128 Relations hôte et microorganismes des épithéliums, Hôpital Côte de Nacre, Université de Caen, 14033 Caen cedex,1 Laboratoire de Microbiologie de l'Environnement, USC INRA2017-EA956, IRBA, Université de Caen, France2
Received 19 February 2005/ Returned for modification 27 March 2005/ Accepted 28 March 2005
Streptococcus agalactiae UCN36 was resistant to lincomycin (MIC = 16 µg/ml) but susceptible to clindamycin (MIC = 0.12 µg/ml) and erythromycin (MIC = 0.06 µg/ml). A 4-kb HindIII fragment was cloned from S. agalactiae UCN36 total DNA on plasmid pUC18 and introduced into Escherichia coli AG100A, where it conferred resistance to lincomycin. The sequence analysis of the fragment showed the presence of a 1,724-bp element delineated by imperfect inverted repeats (22 of 25 bp) and inserted in the operon for capsular synthesis of S. agalactiae UCN36. This element carried two open reading frames (ORF). The deduced amino acid sequence of the upstream ORF displayed similarity with transposases from anaerobes and IS1. The downstream ORF, lnu(C), encoded a 164-amino-acid protein with 26% to 27% identity with the LnuAN2, LnuA, and LnuA' lincosamide nucleotidyltransferases reported for Bacteroides and Staphylococcus, respectively. Crude lysates of E. coli AG100A containing the cloned lnu(C) gene inactivated lincomycin and clindamycin in the presence of ATP and MgCl2. Mass spectrometry experiments demonstrated that the LnuC enzyme catalyzed adenylylation of lincomycin.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |